Mark Ragosa Sells 36,372 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 36,372 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $510,815.50. This represents a 61.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kiniksa Pharmaceuticals Trading Up 2.0 %

Shares of KNSA opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The firm has a fifty day simple moving average of $19.99 and a 200 day simple moving average of $22.16. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same quarter in the previous year, the company posted $0.35 EPS. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year. As a group, research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KNSA has been the subject of several research reports. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 price objective for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $37.17.

Institutional Trading of Kiniksa Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in Kiniksa Pharmaceuticals in the third quarter valued at $50,000. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at $61,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at $158,000. Bellevue Group AG acquired a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at $160,000. Finally, Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after acquiring an additional 4,575 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.